Johnson & Johnson’s new antidepressant could face structural barriers to uptake

0
35

The FDA approved Spravato in March, but a new paper in JAMA examines some of the barriers inherent in the practice and reimbursement of psychiatry that could get in the way of widespread use of the drug.